Dr. Kerrigan’s group is primarily interested in the development of new organocatalytic methodologies that will ultimately be applied in the synthesis of biologically interesting molecules (natural products and drug-like molecules). Other areas of interest include the development of hybrid organocatalyzed/transition metal catalyzed technologies. These would provide access to molecular complexity not available through use of organic molecule or transition metal catalysis alone.
